Key references: Opioid misuse, abuse and diversion
Ballantyne JC. Opioids for the treatment of chronic pain: Mistakes made, lessons learned, and future directions. Anesth Analg 2017;125(5):1769–78. https://www.ncbi.nlm.nih.gov/pubmed/29049121
Coplan PM, Sessler NE, Harikrishnan V, Singh R, Perkel C. Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System. Postgrad Med 2017;129(1):55–61. https://www.ncbi.nlm.nih.gov/pubmed/27922764
Dart RC, Surratt HL, Le Lait MC, Stivers Y, Bebarta VS, Freifeld CC, et al. Diversion and illicit sale of extended release tapentadol in the United States. Pain Med 2016;17(8):1490–6. https://www.ncbi.nlm.nih.gov/pubmed/26814267
Habibollahi P, Garjani A, Shams Vahdati S, Sadat-Ebrahimi SR, Parnianfard N. Severe complications of tramadol overdose in Iran. Epidemiol Health 2019;41:e2019026. https://www.ncbi.nlm.nih.gov/pubmed/31208192
Marteau D, McDonald R, Patel K. The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales. BMJ Open 2015;5(5):e007629. https://www.ncbi.nlm.nih.gov/pubmed/26024998
Mildh LH, Leino KA, Kirvela OA. Effects of tramadol and meperidine on respiration, plasma catecholamine concentrations, and hemodynamics. J Clin Anesth 1999;11(4):310–6. https://www.ncbi.nlm.nih.gov/pubmed/10470633
Murphy DL, Lebin JA, Severtson SG, Olsen HA, Dasgupta N, Dart RC. Comparative rates of mortality and serious adverse effects among commonly prescribed opioid analgesics. Drug Saf 2018;41(8):787–95. https://www.ncbi.nlm.nih.gov/pubmed/29582394
Rodieux F, Vutskits L, Posfay-Barbe KM, Habre W, Piguet V, Desmeules JA, et al. When the safe alternative is not that safe: tramadol prescribing in children. Front Pharmacol 2018;9:148. https://www.ncbi.nlm.nih.gov/pubmed/29556194
Ryan NM, Isbister GK. Tramadol overdose causes seizures and respiratory depression but serotonin toxicity appears unlikely. Clin Toxicol (Phila) 2015;53(6):545–50. https://www.ncbi.nlm.nih.gov/pubmed/25901965
Selden T, Ahlner J, Druid H, Kronstrand R. Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome. Forensic Sci Int 2012;220(1-3):284–90. https://www.ncbi.nlm.nih.gov/pubmed/22565115
Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain 2013;154(11):2287–96. https://www.ncbi.nlm.nih.gov/pubmed/23792283
Tarkkila P, Tuominen M, Lindgren L. Comparison of respiratory effects of tramadol and pethidine. Eur J Anaesthesiol 1998;15(1):64–8. https://www.ncbi.nlm.nih.gov/pubmed/9522144
Tsutaoka BT, Ho RY, Fung SM, Kearney TE. Comparative toxicity of tapentadol and tramadol utilizing data reported to the National Poison Data System. Ann Pharmacother 2015;49(12):1311–6. https://www.ncbi.nlm.nih.gov/pubmed/26369569
van der Schrier R, Jonkman K, van Velzen M, Olofsen E, Drewes AM, Dahan A, et al. An experimental study comparing the respiratory effects of tapentadol and oxycodone in healthy volunteers. Br J Anaesth 2017;119(6):1169–77. https://www.ncbi.nlm.nih.gov/pubmed/29029015
Vosburg SK, Severtson SG, Dart RC, Cicero TJ, Kurtz SP, Parrino MW, et al. Assessment of tapentadol API abuse liability with the researched abuse, diversion and addiction-related surveillance system. J Pain 2018;19(4):439–53. https://www.ncbi.nlm.nih.gov/pubmed/29224919
Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015;156(4):569–76. https://www.ncbi.nlm.nih.gov/pubmed/25785523
Warren PM, Taylor JH, Nicholson KE, Wraith PK, Drummond GB. Influence of tramadol on the ventilatory response to hypoxia in humans. Br J Anaesth 2000;85(2):211–6. https://www.ncbi.nlm.nih.gov/pubmed/10992826
